Home » Stocks » APM

Aptorum Group Limited (APM)

Stock Price: $2.64 USD -0.11 (-4.00%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $2.81 +0.17 (6.44%) Jul 23, 6:46 PM
Market Cap 93.99M
Revenue (ttm) 911,509
Net Income (ttm) 6.31M
Shares Out 13.16M
EPS (ttm) 0.20
PE Ratio 13.20
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $2.64
Previous Close $2.75
Change ($) -0.11
Change (%) -4.00%
Day's Open 2.79
Day's Range 2.58 - 2.80
Day's Volume 113,555
52-Week Range 1.16 - 14.23

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Aptorum Group Limited (NASDAQ: APM) announces further interim data from its ongoing Phase 1 trial for ALS-4 targeting Staphylococcus aureus.  Specifically, two additional cohorts (Cohort C & D) of the s...

1 week ago - Benzinga

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #MRSA--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, ...

1 week ago - Business Wire

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM), a clinical-stage biopharmaceutical company focused on the deve...

2 weeks ago - Business Wire

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group”, the “Company”), a clinical-stage biopharmaceutical company foc...

1 month ago - Business Wire

Which Reddit penny stocks are investors watching right now? Check these 3 out The post 3 Penny Stocks on Reddit Making Big Waves Right Now appeared first on Penny Stocks to Buy, Picks, News and Informat...

Other stocks mentioned: LODE, THMO
2 months ago - PennyStocks

Aptorum Group Limited (NASDAQ: APM) has completed two initial cohorts of the single-dose ascending dose (SAD) portion of the Phase 1 trial evaluating ALS-4 small molecule targeting Staphylococcus aureus...

2 months ago - Benzinga

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceuti...

2 months ago - Business Wire

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceuti...

2 months ago - Business Wire

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM), a clinical-stage biopharmaceutical company dedicated to meeting unmet medical needs...

3 months ago - Business Wire

Aptorum Group Ltd (NASDAQ: APM) has entered into a material transfer and option agreement with Yale University to evaluate a group of preclinical stage novel immunomodulators. Aptorum also obtained an e...

3 months ago - Benzinga

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #autoimmune--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical com...

3 months ago - Business Wire

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #MRSA--Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncol...

3 months ago - Business Wire

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #MRSA--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel...

3 months ago - Business Wire

Aptorum (APM) stock is on the rise Wednesday after announcing approval to move forward with a clinical trial of its staph infection drug. The post APM Stock: 9 Things to Know About Aptorum as Shares Fly...

6 months ago - InvestorPlace

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel t...

6 months ago - Business Wire

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #CTAsubmission--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused...

7 months ago - Business Wire

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the “Company”, “Aptorum Group” or “Aptorum”), a biopharmaceuti...

7 months ago - Business Wire

Aptorum Group has competition in the rapid pathogen identification and detection diagnostics (RPIDD) field. Is APM stock the best bet?

8 months ago - InvestorPlace

Aptorum Group got a boost when the company jumped into the Covid-19 conversation. APM stock looks like a late entry into crowded field.

8 months ago - InvestorPlace

APM stock is a risky name, but the company's recent deal with Singapore has potentially given it a huge opportunity in Asia. The post Why Aptorum's New Singapore Deal Makes It a Worthwhile Buy appeared ...

9 months ago - InvestorPlace

APM stock remains a highly speculative bet for investors as the small biotech company comes with significant risk and volatility. The post Aptorum Group Is Risky, Despite Popularity appeared first on In...

9 months ago - InvestorPlace

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the “Company”, “Aptorum Group” or “Aptorum”), a biopharmaceuti...

9 months ago - Business Wire

APM stock mostly flew under the radar among biotechnology investors. After a recent price surge, though, the stock is now an attention getter.

9 months ago - InvestorPlace

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel techn...

9 months ago - Business Wire

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focus...

9 months ago - Business Wire

Aptorum Group Ltd. (NASDAQ: APM) shares absolutely exploded on Tuesday after the company announced that it would be launching a subsidiary focused on novel technologies targeting infectious diseases. Al...

9 months ago - 24/7 Wall Street

Aptorum Group Ltd (NASDAQ: APM) shares are skyrocketing Tuesday following an announcement concerning the setting up of a subsidiary focused on diagnostic testing. What Happened: U.K.-based Aptorum th...

9 months ago - Benzinga

APM stock is soaring on news that Aptorum Group is launching a subsidiary focused on liquid biopsies for infectious diseases. The post APM Stock: Why Aptorum Group Is Soaring 500% Today appeared first ...

9 months ago - InvestorPlace

NEW YORK, LONDON, & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company f...

9 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (NASDAQ: APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet...

10 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)-- #euronextlisting--Regulatory News: Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a biopharmaceutical company focusing on the development of novel therapeutics to addr...

1 year ago - Business Wire

NEW YORK--(BUSINESS WIRE)-- #Euronext--Regulatory News: Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a biopharmaceutical company focusing on the development of novel therapeutics to address glo...

1 year ago - Business Wire

About APM

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health... [Read more...]

Industry
Biotechnology
IPO Date
Dec 18, 2018
Stock Exchange
NASDAQ
Ticker Symbol
APM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Aptorum Group stock is "Strong Buy." The 12-month stock price forecast is 13.00, which is an increase of 392.42% from the latest price.

Price Target
$13.00
(392.42% upside)
Analyst Consensus: Strong Buy